Jazz Pharmaceuticals appoints vice president of r&d
Jeffrey Tobias also takes chief medical officer role
Tobias has 20 years of experience in the biopharmaceutical industry across all phases of drug development, including regulatory filings in the US and Europe.
He has broad experience with a variety of therapeutic products spanning numerous clinical areas, including pain and neurological disorders.
Most recently, he was executive vice president of research and development at NeurogesX, where he has also been chief medical officer since 2005.
Prior to this Tobias was managing director of an independent biopharmaceutical consulting firm from 1996 to 2006, where he supported clients in all aspects of clinical development, technology assessment and strategic planning. He has also served in various roles in drug discovery and clinical development at ALZA, Chiron and XOMA.
Tobias also has 10 years of experience in clinical and academic medicine, focusing on internal and pulmonary and critical care medicine.
You may also like
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia
AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026